Bosulif® (bosutinib) – Expanded indication
December 19, 2017 – Pfizer announced the FDA approval of Bosulif (bosutinib) for the treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).
Download PDF
